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ABSTRACT 
4-Bromomethylcoumarins (1a-k) were reacted with 8-hydroxyquinolines (2a-b) to yield quinolinoxymethylcoumarins (3a-o). The 
structure of all the synthesized compounds were confirmed by spectral studies and screened for their anticancer activities against 
Dalton’s Ascitic Lymphoma (DAL) and Ehrlich Ascites Carcinoma (EAC) cell lines. Out of these, the compound (3d) (R = 6-Benzyl, 
R1=H) was found to be the most potent cytotoxic compound against DAL cell line with IC50 value of 45.86 µg/mL and the compound 
(3i) (R = 6-i-Pr, R1= CH3) against EAC cell line with IC50 value of 39.26 µg/mL.  
Keywords: 4-Bromomethylcoumarins, Coumarins, Cytotoxic activity, Quinoline.   
 
INTRODUCTION 
any quinoline nucleus containing compounds 
exhibited a wide variety of pharmacological 
and biological activities. 2-Chloro-8-
methylquinolineamine derivatives1 emerged as most 
potential antidepressant agents by forced swim test in 
rats. Bisquinolines2 synthesized from 8-hydroxyquinolines 
possessed significant antibacterial activity against 
Escherichia coli. Quinoline based thiazolidinones3 were 
found to be the most active antifungal agents against 
Candida albicans. β-Aryloxyquinoline derivatives4 were 
emerged as the promising antitubercular member against 
Mycobacterium tuberculosis H37Rv. 3-Arylquinolines5 
were readily synthesized by a novel Friedlander-type 
reaction and explored with the proofs of isolation of the 
enaminone intermediate. 8-Hydroxyquinoline6 is a 
versatile ligand in coordination chemistry which was used 
for analytical purposes.  
Coumarins are known to be biologically versatile 
compounds possessing several biological properties. 
Thiazolidinyl-4-aryloxymethylcoumarins7 were found to 
be potent anti-inflammatory agents by carrageenan 
induced rat paw oedema inhibition method and 
numerous research reports8 have also indicated the 
coumarin nucleus as a potential candidate for 
development of anti inflammatory drugs. Halogenated-4-
aryloxymethylcoumarins9 was found to be potent 
antibacterial agents against Bacillus subtils and 
Escherichia coli. 3,4-Dihydropyridin-2-one-4-aryloxy 
methylcoumarins10 were also found to be potent 
antifungal agents against Penicillium chrysogenum and 
Rhizopus oryzae. 4-Amino-3-(2-methylbenzyl) coumarin 
derivatives11 showed potent estrogenic activity on the 
estrogen receptor positive (ER+) human MCF-7 breast 
cancer cell line. Benzothiazolyl coumarin acetamide 
derivatives12 possessed strong in vitro anti-HIV effect 
against the wild-type HIV-1 cell line. Pyrrole bis 
coumarins, a new structure for florescent probes has 
been reported.13 A protocol for chemoselective one pot 
synthesis of Benzthiazinyl coumarins has been 
developed.14 
On the basis of all of these evidences, we set out to 
synthesize a new series of biologically active compounds 
containing both of these two important pharmacophores. 
This study presents the synthesis, characterization and in 
vitro cytotoxic activities of these new quinolinoxy 
methylcoumarins.       
Chemistry 
Various 4-bromomethylcoumarins (1a-k)15,16 were 
synthesized by the Pechmann cyclisation of phenols with 
4-bromoethylacetoacetate.17 In the same method, we 
have synthesized a novel 4-bromomethyl-6-ethyl 
coumarin (1d) (scheme 1). 
4-Bromomethyl-6-methylcoumarins (1a-k) reacted with 8-
hydroxyquinolines (2a-b) in the presence of anhydrous 
K2CO3 to give 6-methyl-4-(quinolin-8-yloxymethyl)-
chromone-2-one.18 We have extended the same method 
to other substituent of 4-bromomethylcoumarins (1a-k) 
and 8-hydroxyquinolines (2a-b) (Scheme 2). The 
numbering of the skeleton (3e) is shown (Figure 1).  
 
Figure 1: (3e) 
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MATERIALS AND METHODS 
General 
The melting points were determined by open capillary 
method using electric melting point apparatus and are 
uncorrected. The IR spectra (KBr disc) were recorded on a 
Shimadzu-8400S FT-IR Spectrophotometer.  1H NMR, 13C 
NMR and HSQC were recorded on Bruker 400 MHz 
spectrometer by using CDCl3 as a solvent and TMS as an 
internal standard. The chemical shifts are expressed in δ 
ppm. The mass spectra were recorded using Agilent-
Single Quartz LC-MS. The purity of the compound was 
checked by TLC.                                 
 
Scheme 1: Synthesis of 4-Bromomethyl-6-ethylcoumarin (1d) 
 
Scheme 2: Synthesis of quinolinoxymethylcoumarins 3(a=0)         
R = 1a; 6-CH3, 1b; 7-CH3, 1c; 6-OMe, 1d; 6-C2H5, 1e; 6-ipr, 1f; 6-tert-Butyl, 1g; Benzyl, 1h; 5,6-Benzo, 1i; 6-Cl, 1j; 6-Br, 1k; 6-F.  
R1 = 2a; H, 2b; CH3.   
General procedure 
Synthesis of 4-bromomethyl-6-ethylcoumarin (1d) 
To a mixture of equimolar quantity of 4-ethylphenol (5.0 
g, 40.7 mmol) and 4-bromoethylacetoacetate (8.5 mL, 
40.7 mmol) was added drop wise Conc. sulphuric acid 
(5mL) with stirring and maintaining the temperature 
between 0-5°C. The reaction mixture was allowed to 
stand in ice chest overnight and deep red colored solution 
was poured into the stream of crushed ice. Solid 
separated was filtered, washed with water, dried, and 
recrystallized from acetic acid. 
Yield 95%; colorless solid; m.p. 228 0C; IR (KBr, cm‾1) 1701 
cm‾1 (lactone C=O); 1H NMR (400 MHz, CDCl3): δ 1.26 (t, 
3H, CH3 of C2H5, J 1,2 = 8 Hz), 2.71 (q, 2H, CH2 of C2H5, J 1,2 = 
7.6 Hz), 4.50 (s, 2H, CH2-Br), 6.51 (s, 1H, C3-H), 7.26 (d, 1H, 
C8-H, J 1,2 = 5.2 Hz), 7.39 (d, 1H, C7-H, J 1,2 = 10.4 Hz), 7.50 
(s, 1H, C5-H). 
Synthesis of 4-(quinolin-8-yloxymethyl)-chromone-2-one 
(3a-o) 
One of the 8-hydroxyquinolines (2a-b) (3.4 mmol) and 
anhydrous K2CO3 (1.38g, 10mmol) were stirred in 25 ml of 
dry acetone for 30 min. One of the 4-
bromomethylcoumarins (1a-k) (3.4 mmol) was added and 
stirring was continued for 24 h. The reaction mixture was 
concentrated to one fourth volume and poured on to 
crushed ice. The solid separated was filtered and washed 
with 10 ml of 5% HCl. Then, it was washed with 50 ml of 
cold water. The crude product was dried and 
recrystallized from ethanol.   
6-Ethyl-4-(quinolin-8-yloxymethyl)-chromen-2-one (3a)  
Yield 95%; colorless solid; m.p. 204 - 206 0C; IR (KBr, cm‾1) 
1721 cm‾1 (lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
1.25 (t, 3H, CH3 of C2H5), 2.70 (q, 2H, CH2 of C2H5, J1,2 = 7.6 
Hz), 5.64 (S, 2H, OCH2), 6.70(S, 1H, C3-H), 7.05 (d, 1H, C16-
H, J1,2 = 8.4 Hz), 7.30 (d, 1H , C14-H, J1,2 = 8.4 Hz), 7.40 -7.53 
(m, 5H, C5, C7, C8, C15 & C18-H), 8.20 (d, 1H, C17-H, J1,2 = 7.2 
Hz), 9.0 (d, 1H, C19-H, J1,2 = 5.6 Hz). 
6-Isopropyl-4-(quinolin-8-yloxymethyl)-chromen-2-one 
(3b) 
Yield 85%; colorless solid; m.p. 185 - 187 0C; IR (KBr, cm‾1) 
1723 cm‾1 (lactone C=O), 1H NMR (400 MHz, CDCl3): δ 
1.26 (d, 6H, 2-CH3 of isopropyl, J1,2 =6 Hz), 2.9 (septd, 1H, 
CH of isopropyl, J1,2 = 3 Hz), 5.62 (s, 2H, OCH2), 6.70 (s, 1H, 
C3-H), 7.04 (d, 1H, C16-H, J 1,2 = 8.8 Hz), 7.30 (d, 1H , C14-H, 
J1,2 = 8.8 Hz), 7.39 – 7.43 (m, 2H, C5 & C15-H, J1,2 = 10 Hz), 
7.46 - 7.50 (m, 3H, C7, C8 & C17-H, J 1,2 = 2 Hz ), 8.15 (t, 1H, 
C18-H, J 1,2 = 8.4 Hz), 8.96 (d, 1H, C19-H, J 1,2 = 4 Hz). 
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6-Tert-butyl-4-(quinolin-8-yloxymethyl)-chromen-2-one 
(3c) 
Yield 85%; brown solid; m.p. 139 - 141 0C; IR (KBr, cm‾1) 
1690cm‾1 (lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
1.35 (s, 9H, 6-tert-butyl), 5.66 (s, 2H, OCH2), 6.69 (s, 1H, 
C3-H), 7.07 (d, 1H, C14-H, J 1,2 = 7.2 Hz), 7.32 (d, 1H , C8-H, 
J1,2 = 8.8 Hz), 7.44 (t, 1H, C15-H, J 1,2 = 8 Hz), 7.51-7.53 (m, 
2H, C5, C18-H), 7.64 (d, 1H, C16-H, J1,2 = 10.8 Hz), 7.66 (d 
,1H, C7-H, J 1,2 = 2 Hz), 8.21 (d, 1H, C17-H, J 1,2 = 8.4 Hz), 9.0 
(d, 1H, C19-H, J1,2 = 4 Hz). 
6-Benzyl-4-(quinolin-8-yloxymethyl)-chromen-2-one (3d) 
Yield 95%; yellow solid; m.p. 204 - 206 0C; IR (KBr, cm‾1) 
1735 cm‾1 (lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
4.06 (s, 2H, C6-CH2), 5.58 (s, 2H, OCH2), 6.71 (s, 1H, C3-H), 
7.03-8.99 (m, 14H, Ar-H). 
6-Methyl-4-(2-methyl-quinolin-8-yloxymethyl)-chromen-2-
one (3e) 
Yield 95%; colorless solid; m.p. 219 - 221 0C; IR (KBr, cm‾1) 
1716 cm‾1  (lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
2.38 (s, 3H, 6-CH3), 2.75 (s, 3H, C19-CH3), 5.55 (s, 2H, 
OCH2), 6.68 (s, 1H, C3-H), 6.94 (d, 1H, C7-H, J1,2 = 7.6 Hz), 
7.19 (d, 1H, C8-H, J1,2 = 6.4 Hz), 7.23 (d, 1H, C14-H, J1,2 = 6.8 
Hz), 7.26-7.32 (m, 2H, C15, C16-H), 7.35 (d, 1H, C17-H, J1,2 = 8 
Hz), 7.44 (s , 1H, C5-H), 7.97 (d, 1H, C18-H, J1,2 = 8.4 Hz): 13C 
NMR (400 MHz, CDCl3): δ 21.4 (C-23), 26.2 (C-24), 67.2 (C-
11), 111.4 (C-3), 114.0 (C-14), 117.4 (C-16), 117.5 (C-8), 
121.7 (C-15), 123.2 (C-18), 123.7 (C-22), 125.7 (C-10), 
128.3 (C-7), 133.3 (C-5), 134.5 (C-6), 136.5 (C-17), 140.4 
(C-21), 150.3 (C-9), 152.2 (C-13), 153.3 (C-19), 159.0 (C-4), 
161.1 (C-2).  
7-Methyl-4-(2-methyl-quinolin-8-yloxymethyl)-chromen-2-
one (3f) 
Yield 95%; colorless solid; m.p. 256 - 260 0C; IR (KBr, cm‾1) 
1721 cm‾1 (lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
2.42 (s, 3H, 7-CH3), 2.79 (s, 3H, C19-CH3), 5.57 (s, 2H, 
OCH2), 6.64 (s, 1H, C3-H), 6.96 (d, 1H, C6-H, J1,2 = 7.6 Hz), 
7.16 (d, 1H, C5-H, J1,2 = 6.4 Hz), 7.22 (d, 1H, C14-H, J1,2 = 6.8 
Hz), 7.30 (d, 1H, C17-H, J1,2 = 8 Hz), 7.35 (m, 2H, C15, C16-H), 
7.42 (s , 1H, C8-H), 8.0 (d, 1H, C18-H, J1,2 = 8.4 Hz). 
6-Methoxy-4-(2-methyl-quinolin-8-yloxymethyl)-chromen-
2-one (3g) 
Yield 85%; yellow solid; m.p. 197 - 199 0C; IR (KBr, cm‾1) 
1704 cm‾1 (lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
2.80 (s, 3H, C19-CH3), 3.80 (s, 3H, OCH3), 5.61 (s, 2H, 
OCH2), 6.75 (s, 1H, C3-H), 7.04 (d ,1H, C7-H, J1,2 = 6.8 Hz), 
7.15 (d, 1H ,C14-H, J1,2 = 6.4 Hz), 7.24 (d, 1H, C16-H, J1,2 = 2.8 
Hz), 7.31-7.36 (m, 3H, C5, C8 & C15-H), 7.44 (d, 1H, C17-H, 
J1,2 = 8.4 Hz), 8.10 (d ,1H, C18-H, J1,2 = 8.4 Hz). 
6-Ethyl-4-(2-methyl-quinolin-8-yloxymethyl)-chromen-2-
one (3h) 
Yield 95%; colorless solid; m.p. 264 - 266 0C; IR (KBr, cm‾1) 
1734 cm‾1(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
1.26 (t, 3H, CH3 of C2H5, J1,2 = 7.6 Hz), 2.7 (q, 2H, CH2 of 
C2H5), 2.81 (s, 3H, C19-CH3), 5.63 (s, 2H, OCH2), 6.75 (s, 1H, 
C3-H), 7.02 (d, 1H, C14-H, J1,2 = 7.2 Hz), 7.31-7.37 (m, 5H, 
C7, C8, C15-H), 7.40-7.44 (m, 2H , C16 & C17-H), 7.52 (s, 1H, 
C5-H), 8.0 (d, 1H, C18-H, J1,2 = 8.4 Hz). 
6-Isopropyl-4-(-2-methyl-quinolin-8-yloxymethyl)-
chromen-2-one (3i) 
Yield 96%; colorless solid; m.p. 193 - 195 0C; IR (KBr, cm‾1) 
1723 cm‾1 (lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
1.26 (d, 6H, 2-CH3 of isopropyl, J1,2 =6 Hz), 2.75 (s, 2H, C19-
CH3), 2.95 (septd, 1H, CH of isopropyl, J1,2 = 3 Hz), 5.62 (S, 
2H, OCH2), 6.70 (s, 1H, C3-H), 7.04 (d, 1H, C16-H, J1,2 = 8.8 
Hz), 7.30 (d, 1H , C14-H, J1,2 = 8.8 Hz), 7.39 - 7.43 (m, 2H, C7 
& C16-H), 7.45-7.48 (m, 3H, C5, C15 & C17-H, J1,2 = 4.4 Hz), 
7.50(d, 1H, C8-H, J1,2 = 2 Hz ), 8.15 (d, 1H, C18-H, J1,2 = 8.4 
Hz). 
6-Tert-Butyl-4-(2-methyl-quinolin-8-yloxymethyl)-
chromen-2-one (3j)  
Yield 75%; brown solid; m.p. 179 - 182 0C; IR (KBr, cm‾1) 
1718 cm‾1(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
1.36 (s, 9H, 6-tert-butyl), 2.80 (s, 3H, C19-CH3), 5.65 (s, 2H, 
OCH2), 6.74 (s, 1H, C3-H), 7.03 (d, 1H, C7-H, J1,2 = 7.2 Hz), 
7.32-7.36 (m, 3H, C8, C15 & C16-H), 7.44 (d, 1H, C14-H, J1,2 = 
7.2 Hz), 7.60 (d ,1H, C17-H, J1,2 = 6.4 Hz), 7.68 (s, 1H, C5-H), 
8.03 (d, 1H, C18-H, J1,2 = 8.4 Hz) 
6-Benzyl-4-(2-methyl-quinolin-8-yloxymethyl)-chromen-2-
one (3K) 
Yield 60%; colorless solid; m.p. 233 - 235 0C; IR (KBr, cm‾1) 
1728 cm‾1(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
2.41 (s, 3H, C19-CH3), 2.78 (s, 2H, C6-CH2), 5.67 (s, 2H, 
OCH2), 6.8 (s, 1H, C3-H), 7.05-8.10 (m, 13H, Ar-H).  
1-(2-Methyl-quinolin-8-yloxymethyl)-benzo(f)chromen-3-
one (3l) 
Yield 85%; yellow solid; m.p. 197 - 199 0C; IR (KBr, cm‾1) 
1723 cm‾1(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
2.81 (s, 3H, C19-CH3), 6.07 (s, 2H, OCH2), 6.98-8.40 (m, C3-
H & 11H, Ar-H). 
 6-Chloro-4-(2-methyl-quinolin-8-yloxymethyl)-chromen-2-
one (3m) 
Yield 70%; colorless solid; m.p. 216 - 218 0C; IR (KBr, cm‾1) 
1712 cm‾1(lactone C=O);  1H NMR (400 MHz, CDCl3): δ 
2.80 (s, 3H, C19-CH3), 5.66 (s, 2H, OCH2), 6.74 (s, 1H, C3-H), 
7.03 (d, 1H, C8-H, J1,2 = 7.2 Hz), 7.32-7.36 (m, 3H, C7, C14 & 
C-15H), 7.42 (d, 1H, C16-H, J1,2 = 7.2 Hz), 7.60 (d ,1H, C17-H, 
J1,2 = 6.4 Hz), 7.68 (s, 1H, C5-H), 8.02 (d, 1H, C18-H, J1,2 = 8.4 
Hz) 
6-Bromo-4-(2-methyl-quinolin-8-yloxymethyl)-chromen-2-
one (3n) 
Yield 73%; brown solid; m.p. 238 - 240 0C; IR (KBr, cm‾1) 
1719 cm‾1(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
2.82 (s, 3H, C19-CH3), 5.55 (s, 2H, OCH2), 6.81 (s, 1H, C3-H), 
7.07-8.06 (m, 8H, Ar-H). 
6- Fluoro-4-(2-methyl-quinolin-8-yloxymethyl)-chromen-2-
one (3o) 
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Yield 65%; colorless solid; m.p. 226 - 228 0C; IR (KBr, cm‾1) 
1704 cm‾1(lactone C=O); 1H NMR (400 MHz, CDCl3): δ 
2.80 (s, 3H, C19-CH3), 5.60 (s, 2H, OCH2), 6.75 (s, 1H, C3-H), 
7.04 (d ,1H, C7-H, J1,2 = 6.8 Hz), 7.15 (d, 1H , C16-H, J1,2 = 6.4 
Hz), 7.24 (d, 1H, C14-H, J1,2 = 2.8 Hz), 7.32-7.38 (m, 3H, C5, 
C8 & C15-H), 7.44 (d, 1H, C17-H, J1,2 = 8.4 Hz), 8.10 (d ,1H, 
C18-H, J1,2 = 8.4 Hz). 
Biological activity 
The cytotoxic activity of newly synthesized compounds 
was examined in vitro on Dalton’s Lymphoma Ascites 
(DAL) and Ehrlich Ascites Carcinoma (EAC) cells using 
Trypan blue dye exclusion assay.19 
Ascitic fluid withdrawn from the peritoneum of DAL and 
EAC inoculated mouse was washed with ice cold 
phosphate buffer saline (PBS) (pH 7.4). Stock cell 
suspension was adjusted to 1×106 cell / 0.2 mL by PBS 
using hemocytometer. The cells were incubated with 
desired test drug concentration in a final volume of 1mL 
for 3h at 37 0C in CO2 incubator with continuous flow of 
5% CO2, 5-Fluorouracil was used as positive control. After 
incubation, 0.2 mL of cell line was taken and made up to 
final concentration with PBS (0.3 mL), trypan blue (0.5 
mL), mixed well and kept aside for 5 min. The total 
number of dead and living cells was counted using a 
hemocytometer and the percentage viability or 
cytotoxicity was calculated. All the procedures were done 
in triplicate manner. 
RESULTS AND DISCUSSION 
In the IR spectrum of 4-bromomethyl-6-ethylcoumarin 
(1d) (R = 6-ethyl), the lactone carbonyl stretching 
frequency was observed at 1701 cm−1. The 1H NMR 
spectrum of compound (1d) exhibited a singlet at δ 4.50, 
6.51 and 7.50 due to CH2-Br, C3-H and C5-H protons 
respectively. A triplet and a quartet were observed at δ 
1.26 (J1,2 = 8 Hz) and 2.71 (J1,2 = 7.6 Hz), due to methylene 
and methyl protons of ethyl group. The C7-H and C8-H 
protons were found to resonate as a doublet at δ 7.39 
(J1,2 = 10.4 Hz) and 7.26 (J1,2 = 5.2 Hz) respectively. 
In the IR spectrum of 6-methyl-4-(2-methyl-quinolin-8-
yloxymethyl)-chromen-2-one (3e) (R = 6-CH3, R1= CH3), the 
lactone carbonyl stretching frequency was appeared at 
1716 cm−1. The 1H NMR spectrum of the compound (3e) 
displayed a singlet at δ 2.38, 5.55, 6.68 and 7.44 due to 
C19-CH3, OCH2, C3-H and C5-H protons respectively.  The 
C7, C8, C14, C17 and C18-H protons resonated as a doublet at 
δ 6.96 (J1,2 = 7.6 Hz), 7.20 (J1,2 = 6.4 Hz), 7.23(J1,2 = 6.8 Hz), 
7.37(J1,2 = 8 Hz) and 7.99(J1,2 = 8.4 Hz) respectively. The 
multiplet appeared in the range of 7.32-7.35 was due to 
C15-H and C16-H respectively. 
The 13C NMR spectral data of compound (3e) is given in 
the method and materials section, which is confirmed by 
its HSQC spectrum.  
In vitro anticancer screening 
The newly synthesized compounds (3a-o) were evaluated 
for their in vitro cytotoxic activity against Dalton’s 
Lymphoma Ascites (DAL) and Ehrlich Ascites Carcinoma 
(EAC) Cells. 5-Fluorouracil which is one of the most 
effective anticancer agents was used as the reference 
drug in this study. 
The relationship between surviving fraction and drug 
concentration was plotted to obtain the survival curve of 
Dalton’s Lymphoma Ascites (DAL) and Ehrlich Ascites 
Carcinoma (EAC) cells. The response parameter calculated 
was the IC50 value, which corresponds to the 
concentration required for 50% inhibition of cell viability. 
The IC50 of the synthesized compounds compared to the 
reference drug are shown in Table 1 and the result is 
represented graphically in Figure 2. 
Table 1: Result of in vitro cytotoxic activity of the 
synthesized compounds against DAL & EAC cells. 
Compound R R1 DAL IC50 EAC IC50 
3a 6-C2H5 H 70.58 59.20 
3b 6-i-Pr H 97.19 79.26 
3c 6-tert-butyl H 78.54 63.47 
3d 6-Benzyl H 45.85 93.99 
3e 6-CH3 CH3 74.21 59.26 
3f 7-CH3 CH3 150.48 48.84 
3g 6-OCH3 CH3 140.87 46.26 
3h 6-C2H5 CH3 143.25 78.24 
3i 6-i-Pr CH3 54.28 39.26 
3j 6-tert-butyl CH3 74.68 46.20 
3k 6-Benzyl CH3 154.25 62.99 
3l 5,6-Benzo CH3 107.88 96.20 
3m 6-Cl CH3 67.81 78.65 
3n 6-Br CH3 54.25 109.34 
3o 6-F CH3 65.24 61.26 
5-Fluorouracil 41.61 41.61 
The investigation of in vitro cell cytotoxicity against DAL 
cell revealed that the most of the tested compounds 
exhibited good activity. The Compound (3d) (R = 6-Benzyl, 
R1 = H) was the most potent compound in this screening 
against DAL cell with IC50 value of 45.86 µg/mL. The 
compounds (3i) (R = 6-i-Pr, R1 = CH3), (3m) (R = 6-Cl, R1 = 
CH3), (3n) (R = 6-Br, R1 = CH3) and (3o) (R = 6-F, R1 = CH3) 
were found to be highly active against DAL cell with IC50 
between 54.25 and 67.81 µg/mL. The compounds (3a) (R 
= 6-Ethyl, R1 = H), (3b) (R = 6-i-Pr, R1 = H), (3c) (R = 6-tert-
butyl, R1 = H), (3e) (R = 6-CH3, R1 = CH3) and (3j) (R = 6-
tert-butyl, R1 = CH3) showed moderate activity against 
DAL cell with IC50 between 74.21 and 97.19 µg/mL. The 
compounds (3f) (R = 7-CH3, R1 = CH3), (3g) (R = 6-OCH3, R1 
= CH3), (3h) (R = 6-Ethyl, R1 = CH3), (3k) (R = 6-Benzyl, R1 = 
CH3) and (3l) (R = 5,6-Benzo, R1 = CH3) showed poor 
activity against DAL cell with IC50 between 107.88 and 
150.48 µg/mL. 
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Figure 2: IC50 µg/mL of the synthesized compounds and 5-
Flourouracil against DAL & EAC cells. 
The investigation of in vitro cell cytotoxicity against EAC 
cell revealed that the most of the tested compounds 
exhibited good activity. The Compound (3i) (R = 6-i-Pr, R1 
= CH3) was found to be highly active against EAC cell with 
IC50 value of 39.26 µg/mL. The compounds (3a) (R = 6-
Ethyl, R1 = H), (3c) (R = 6-tert-butyl, R1=H), (3e) (R = 6-CH3, 
R1 = CH3), (3f) (R = 7-CH3, R1 = CH3), (3g) (R = 6-OCH3, R1 = 
CH3), (3j) (R = 6-tert-butyl, R1 = CH3), (3k) (R = 6-Benzyl, R1 
= CH3) and (3o) (R = 6-F, R1 = CH3) were found to be highly 
active against EAC cell with IC50 between 46.20 and 63.47 
µg/mL. The compounds (3b) (R = 6-i-Pr, R1 = H), (3d) (R = 
6-Benzyl, R1=H), (3h) (R = 6-Ethyl, R1=CH3), (3l) (R = 5,6-
Benzo, R1 = CH3) and (3m) (R = 6-Cl, R1 = CH3) showed 
moderate activity against EAC cell with IC50 between 
78.24 and 96.20 µg/mL. The compounds (3n) (R= 6-Br, R1 
= CH3) showed poor activity against EAC cell with IC50 
109.34 µg/mL. 
CONCLUSION 
Introduction of benzyl group at 6-position of coumarin 
ring is found to enhance the cytotoxicity against DAL cell 
and also, introduction of isopropyl group at 6-position of 
coumarin ring and methyl group at 2-position of quinoline 
ring is found to enhance the cytotoxicity against EAC cell. 
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